Tenet Healthcare Corporation (THC)
NYSE: THC · Real-Time Price · USD
152.27
+3.89 (2.62%)
Jul 25, 2025, 3:12 PM - Market open
Tenet Healthcare Stock Forecast
Stock Price Forecast
The 16 analysts that cover Tenet Healthcare stock have a consensus rating of "Buy" and an average price target of $191.56, which forecasts a 25.8% increase in the stock price over the next year. The lowest target is $154 and the highest is $238.
Price Target: $191.56 (+25.8%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tenet Healthcare stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 10 | 11 | 9 | 10 | 9 | 10 |
| Hold | 3 | 3 | 4 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 19 | 18 | 17 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Hold Maintains $195 → $167 | Hold | Maintains | $195 → $167 | +9.67% | Jul 25, 2025 |
| Barclays | Barclays | Buy Maintains $215 → $208 | Buy | Maintains | $215 → $208 | +36.60% | Jul 24, 2025 |
| UBS | UBS | Strong Buy Maintains $230 → $238 | Strong Buy | Maintains | $230 → $238 | +56.30% | Jul 23, 2025 |
| Raymond James | Raymond James | Buy Reiterates $185 → $200 | Buy | Reiterates | $185 → $200 | +31.35% | Jul 23, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $180 → $188 | Strong Buy | Maintains | $180 → $188 | +23.46% | Jul 23, 2025 |
Financial Forecast
Revenue This Year
21.13B
from 20.67B
Increased by 2.24%
Revenue Next Year
22.18B
from 21.13B
Increased by 4.99%
EPS This Year
12.95
from 32.70
Decreased by -60.41%
EPS Next Year
13.88
from 12.95
Increased by 7.18%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.3B | 23.5B | 24.8B | ||
| Avg | 21.1B | 22.2B | 23.4B | ||
| Low | 20.3B | 21.1B | 21.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.8% | 11.4% | 11.6% | ||
| Avg | 2.2% | 5.0% | 5.4% | ||
| Low | -1.9% | -0.3% | -1.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.71 | 16.41 | 19.49 | ||
| Avg | 12.95 | 13.88 | 15.71 | ||
| Low | 12.05 | 11.35 | 12.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -55.0% | 26.8% | 40.4% | ||
| Avg | -60.4% | 7.2% | 13.2% | ||
| Low | -63.1% | -12.3% | -7.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.